ALDX — Aldeyra Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1341235 ·
Last close
$0.69
Market Cap
$41.88M
52W High
$5.93
52W Low
$0.53
ADV30
953,351
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,136,274 | -3,762,964 | 43,381,909 | 40,974,979 | 8,159,697 |
| Jun 2026 | 0 | — | -5,850,507 | -5,450,273 | 47,540,559 | 45,089,786 | 9,655,256 |
| Mar 2026 | 0 | — | -3,546,918 | -3,452,619 | 66,483,081 | 65,002,305 | 24,326,289 |
| Dec 2025 | 0 | — | -6,667,883 | -6,461,507 | 72,059,317 | 70,041,254 | 27,808,927 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,020,272
Investing CF
$40,976,903
Financing CF
$-15,108,114
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-492,860,145
Inventory
—
Receivables
$755,545
ST Investments
$0
EBIT TTM
$-21,632,877
Pretax Income TTM
$-23,052,740
Interest Exp TTM
$1,419,863
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -35,265,206 | -33,846,661 | 72,059,317 | 27,808,927 | 44,250,390 | -33,345,682 |
| Dec 2024 | 0 | -60,117,032 | -55,851,444 | 104,606,694 | 33,601,823 | 71,004,871 | -43,208,747 |
| Dec 2023 | 0 | -42,794,083 | -37,542,510 | 148,326,911 | 28,531,881 | 119,795,030 | -30,326,128 |
| Dec 2022 | 0 | -62,679,987 | -62,024,636 | 181,291,657 | 30,283,628 | 151,008,029 | -56,637,187 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$2,433,564
NetIncome TTM
$-23,052,740
OpCashFlow TTM
—
Assets (Latest)
$47,540,559
Forward EPS
$-0.28
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.67 · call volume: 11 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLPH | TALPHERA, INC. | $41.61M | $0.80 | — |
| ATNM | Actinium Pharmaceuticals, Inc. | $42.45M | $1.35 | — |
| DWTX | Dogwood Therapeutics, Inc. | $41.29M | $1.08 | — |
| HYFT | MindWalk Holdings Corp. | $42.60M | $0.91 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $40.93M | $0.66 | — |
News headlines (Yahoo Finance, 1h cache)
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
2026-09-29 15:02 · Yahoo
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
2026-09-29 14:49 · Yahoo
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
2026-09-29 11:00 · Yahoo
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
2026-10-15 13:33 · Yahoo
Here's Why You Should Add ANRO Stock to Your Portfolio Now
2026-10-14 12:59 · Yahoo
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
2026-10-14 12:52 · Yahoo
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
2026-10-12 15:24 · Yahoo
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
2026-10-12 14:55 · Yahoo
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
2026-10-09 16:55 · Yahoo
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
2026-10-09 14:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.